###### Strengths and limitations of this study

-   The use of multiple sources of case ascertainment reduces potential influence of selection bias.

-   The inclusion of all age groups and those with either a clinical or molecular confirmation of diagnosis is important for public health planning.

-   Presentation of age-standardised prevalence enables comparison of prevalence across different countries, important in understanding the global burden and population trends.

-   Low rates of neurophysiology and molecular confirmation of diagnosis were observed, indicating difficulties with access or uptake of neurophysiology and genetic testing in New Zealand (NZ).

-   To respect patient privacy and adhere to data sharing policies in NZ, it was difficult to identify family relationships between individually identified patients across different organisations.

Introduction {#s1}
============

Charcot-Marie-Tooth disease (CMT) encompasses a group of genetically and phenotypically diverse disorders primarily characterised by demyelination of the nerves or degeneration of the axons.[@R1] CMT is divided into mutation-specific subtypes, with all types of Mendelian inheritance patterns observed.[@R3] CMT1 has been reported to be the most common type, accounting for between 37.6% and 84.0% of cases.[@R4] Symptoms include weakness and wasting of the muscles (predominantly distally in the legs and arms), cavovarus foot deformity (high arched feet), chronic pain, muscle cramps, impaired balance and paraesthesia.[@R5] Most symptoms become apparent after 5 years of age and adversely impact on the affected person's physical/emotional functioning and quality of life.[@R5]

Accurate prevalence data are important to inform healthcare service planning and resourcing as well as to provide an indication of the scope of societal burden. However, a recent systematic review of epidemiological studies of CMT revealed extremely variable prevalence from 9.7 per 100 000 in Serbia to 82.3 per 100 000 in Norway.[@R4] The reason for the substantially higher prevalence reported in Norway is unclear, but is likely to be due to different case ascertainment methods (use of medical records within a relatively small population sample of 300 000) and possible founder effects.[@R7] Excluding the study in Norway as an outlier, average prevalence was 14.5 per 100 000.[@R4] Published studies vary considerably in their methodological quality and methodologies, which makes comparisons challenging.[@R4] Existing studies have depended heavily on medical records to identify cases and may have underestimated cases by excluding those who received a diagnosis outside of the study area or if the person was self-managing in the community.[@R4] Additionally, there were no identified studies conducted in Asia-Pacific. A recent study conducted in Ireland, which did use multiple case ascertainment sources (including patient support organisations) was limited as prevalence was restricted to those \>18 years of age.[@R9] The current study aimed to determine subtype, age and sex-specific prevalence of CMT in Auckland, New Zealand (NZ), using both clinical and community-based sources of case ascertainment across the lifespan.

Patients and methods {#s2}
====================

Setting {#s2a}
-------

The Auckland Region ([figure 1](#F1){ref-type="fig"}) is the most populated area of NZ, with 33% of the population residing in the region (national population=4 242 048).[@R10] The population denominator for the Auckland Region (1 415 550) was determined by 2013 NZ census data.[@R10] The New Zealand National Health Service provides residents with healthcare for medical conditions not caused by an accident.

![Map of New Zealand showing location of Auckland Region in the North Island of New Zealand (shaded).](bmjopen-2019-029240f01){#F1}

Identification of study population {#s2b}
----------------------------------

This epidemiological study aimed to identify all adults and children with a confirmed clinical or molecular diagnosis of CMT, living in the Auckland Region of NZ on the point prevalence date of 1 June 2016. Cases were ascertained using multiple overlapping sources. Keyword diagnostic searches and International Classification of Disease code (G60.0.356.1) were used to search neurologists' patient lists (private and publicly funded services), hospital admission and discharge records, genetic services database and the national health database. Keyword searches were used to identify cases from the NZ Muscular Dystrophy Association (MDA-NZ) membership database, and NZ Neuromuscular Disease Registry.[@R11] Local health professionals including podiatrists, orthotics clinics, physiotherapists, speech and language therapists and general practitioners within the Auckland region of NZ were contacted to invite their patients into the study, as well as circulating leaflets for display in healthcare clinics. Additionally, national and regional disability services and culturally specific patient support organisations were asked to contact clients with the included conditions to inform them about the study and invite them to participate. Local media coverage (including newspaper advertisements and a Facebook page) were used to encourage self-referrals into the study. A freephone number was set up to facilitate direct contact with the study team. Interpreters were provided if required to facilitate participation in the study.

Searches of healthcare records were conducted by a member of staff employed by each participating organisation to protect patient confidentiality. Only demographic information (including sex, ethnicity and region of residence) and details of diagnosis were obtained for each new case (no names and addresses were required). In NZ, all citizens are routinely allocated a unique patient identification number enabling duplicate identification of cases from across multiple databases without the need for patient identifiers. Following completion of case ascertainment, National Health Index (NHI) numbers were removed from the main study database and kept in a separate password-protected file to protect patient confidentiality and data security.

Following identification, participants were contacted by the staff member at each organisation via phone, email or letter to provide them with brief information about the study. Participants interested in finding out more about the study were asked for their permission to share their contact details with the research team or to contact the research team directly. Written informed consent was obtained by the research team and further details about the person were collected. For participants who were not able to be contacted and those who did not wish to take part further, only the anonymised data on sex, ethnicity, region of residence and diagnosis were used.

Verification of diagnosis was obtained for all potentially eligible cases based on the NHI number from medical records, and clinical investigations which were provided with name and address details 'blanked out'. Where there was supportive neurophysiology, we specified the subtype as type 1 demyelinating, type 2 (axonal) or intermediate. Any molecular confirmation of diagnosis was obtained from the NZ Genetics Service. For participants who had not had neurophysiological or genetic testing themselves, but who had a first-degree or second-degree relatives with a confirmed diagnosis, it was assumed that they had the same subtype. The study neurologists reviewed any cases where diagnosis was unclear. If there was insufficient evidence to verify a clinical diagnosis, the case was excluded.

All identified cases were checked against the national death registry to confirm living status on the point prevalence date.

Patient and public involvement {#s2c}
------------------------------

Patients were not involved directly in the study design or analysis. The study was conducted in partnership with the MDA-NZ who represented the views of people living with CMT and their preferences. The findings of the study were mailed/emailed directly to participants following completion of the study. A summary of the results was also disseminated to participants through the study Facebook page, MDA-NZ patient newsletter and member meetings.

Statistical analysis {#s2d}
--------------------

Population demographics including age, sex and ethnicity of the Auckland region were extracted from the 2013 census and used as the population denominator.[@R10] Direct standardisation was used to age-standardise the rates to the world population for international comparability.[@R12] Prevalence by age, sex and diagnostic subtype was calculated per 100 000 population with 95% CIs using the Poisson distribution.

Results {#s3}
=======

A total of 296 potentially eligible participants were identified and screened, 60 were deemed ineligible ([figure 2](#F2){ref-type="fig"}). Two hundred thirty-six adults (≥16 years, n=207, 87.7%) and children (\<16 years, n=29, 12.3%) met the inclusion criteria. Participants were aged between 3 months and 94 years of age (mean age on point prevalence date of 43.4, SD 22.7). Mean age at diagnosis was 34.1 (SD 22.1). Half of the sample were males (n=119, 50.4%), with the majority (n=170, 72.0%) being of NZ European ethnicity. Of the 236 eligible participants, the majority (93.2%) of the sample were identified by healthcare services (neurologist, hospital, genetics and health laboratories), 6.8% of participants were not known to healthcare services and were uniquely identified through the NZ Neuromuscular Disease Registry or through community services and family/self-referrals ([figure 3](#F3){ref-type="fig"}). Over half of participants (n=139, 58.9%) indicated that at least one other family member was also affected by CMT. There were 48 participants with one other known affected member, 17 with 2 and 18 participants indicated there were 3--5 members of their family diagnosed with CMT, most of whom had also been captured within the study.
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![Multiple case ascertainment by all source types. NZ, New Zealand.](bmjopen-2019-029240f03){#F3}

The overall crude point prevalence in Auckland, NZ on the point prevalence date was 16.7 per 100 000 (95% CI 14.6 to 19.0). After age adjustment according to the world standard population (to account for international population differences), prevalence of CMT was 15.7 per 100 000 (95% CI 11.6 to 21.0). This translates to one in every 6369 people in the Auckland Region of NZ with CMT. As expected CMT1A was the most common subtype (40.9% of cases) with a prevalence of 6.9 per 100 000 (95% CI 5.6 to 8.4) as shown in [table 1](#T1){ref-type="table"}. Of the 146 (61.1%) participants who had received a genetic test, the test provided molecular confirmation of diagnosis for 99 (41.9%) people. Of the 138 people who did not receive a molecular confirmation of diagnosis following a genetic test or who received an unconfirmed result, 79 (57.2%) had received a neurophysiology test.

###### 

Prevalence of CMT subtypes

  CMT subtype            N     Prevalence per 100 000   95% CI
  ---------------------- ----- ------------------------ --------------
  CMT1A (PMP22 dup)      97    6.9                      5.6 to 8.4
  HNPP (PMP22del)        18    1.3                      0.8 to 2.1
  CMT1B (MPZ)            2     0.1                      0.0 to 0.6
  CMT1 (other)\*         17    1.2                      0.7 to 2.0
  CMT2A (mitofusion 2)   2     0.1                      0.0 to 0.6
  CMT2C (TRPV4)          1     0.1                      0 to 0.5
  CMT2M (Dynamin 2)      1     0.1                      0 to 0.5
  CMT2 (other)\*         30    2.1                      1.5 to 3.1
  CMTX1 (GJB1)           5     0.4                      0.1 to 0.9
  CMTX3                  1     0.1                      0 to 0.5
  CMTX (other)†          6     0.4                      0.2 to 1.0
  HMN                    2     0.1                      0.0 to 0.6
  HSN (HSAN1)            1     0.1                      0 to 0.5
  Unclassified           53    3.7                      2.8 to 4.9
  Total                  236   16.7                     14.6 to 19.0

\*Cases classified based on nerve conduction study results.

†Based on family history and clinical presentation.

CMT, Charcot-Marie-Tooth.

As shown in [table 2](#T2){ref-type="table"}, age-standardised prevalence was slightly higher in males (16.6 per 100 000, 95% CI 10.9 to 25.2) than females (14.6 per 100 000, 95% CI 9.6 to 22.4). Highest prevalence (25.2 per 100 000, 95% CI 19.4 to 32.6) was observed in those aged 50--64 years. There were surprisingly few young females under the age of 15 years. Prevalence for those were aged 16 years or over was 18.7 per 100 000 (95% CI 15.4 to 22.6).

###### 

Prevalence of Charcot-Marie-Tooth disease by age and sex

                    Total population (n)   Number of cases (%)   Prevalence per 100 000   95% CI
  ----------------- ---------------------- --------------------- ------------------------ ----------------
  Boys and men                                                                            
   0--14 years      151 839                19 (16.0)             12.5                     (7.8 to 20.0)
   15--34 years     200 958                32 (26.9)             15.9                     (11.1 to 22.8)
   35--49 years     143 652                19 (16.0)             13.2                     (8.2 to 21.1)
   50--64 years     116 796                29 (24.4)             24.8                     (16.9 to 36.2)
   ≥65 years        74 244                 20 (16.8)             26.9                     (16.9 to 42.4)
   Total            687 492                119 (100.0)           17.3                     (14.4 to 20.8)
   Standardised     --                     --                    16.6                     (10.9 to 25.2)
  Girls and women                                                                         
   0--14 years      144 516                8 (6.8)               5.5                      (2.6 to 11.4)
   15--34 years     208 659                27 (23.1)             12.9                     (8.7 to 19.1)
   35--49 years     160 485                29 (24.8)             18.1                     (12.3 to 26.3)
   50--64 years     125 284                32 (27.4)             25.5                     (17.8 to 36.5)
   ≥65 years        88 905                 21 (18.0)             23.6                     (15.0 to 36.8)
   Total            728 058                117 (100.0)           16.1                     (13.4 to 19.3)
   Standardised     --                     --                    14.6                     (9.6 to 22.4)
  Total sample                                                                            
   0--14 years      296 358                27 (11.4)             9.1                      (6.1 to 13.5)
   15--34 years     409 620                59 (25.0)             14.4                     (11.1 to 18.1)
   35--49 years     304 134                48 (20.3)             15.8                     (11.8 to 21.1)
   50--64 years     242 280                61 (25.9)             25.2                     (19.4 to 32.6)
   ≥65 years        163 152                41 (17.4)             25.1                     (18.3 to 34.4)
   Total            1 415 550              236 (100.0)           16.7                     (14.6 to 19.0)
   Standardised\*   --                     --                    15.6                     (11.6 to 21.0)

\*Standardised to the WHO standard population.

As shown in [table 3](#T3){ref-type="table"}, nearly half of all cases had a demyelinating CMT phenotype. While a higher proportion of females had an axonal phenotype than males, this difference was not significant (χ^2^=0.85, p=0.36).

###### 

Charcot-Marie-Tooth (CMT) phenotype by gender

  ----------------------------------------------------------------
                         Males\        Females\      Total\
                         N (%)         N (%)         N (%)
  ---------------------- ------------- ------------- -------------
  Demyelinating (CMT1)   55 (46.2)     55 (46.6)     110 (46.4)

  Axonal (CMT2)          16 (13.4)     20 (17.1)     36 (15.3)

  Intermediate           9 (7.6)       4 (3.4)       13 (5.5)

  Unclassified           39 (32.8)     38 (32.2)     77 (32.5)

  Total                  119 (100.0)   117 (100.0)   236 (100.0)
  ----------------------------------------------------------------

Discussion {#s4}
==========

This study using multiple case ascertainment sources and presenting age-standardised data reveals 15.7 per 100 000 people are affected by CMT in Auckland, the largest region of NZ. Community case ascertainment sources were critical to the accuracy of prevalence findings, with 6.8% of cases uniquely identified through the community or the national neuromuscular disease registry. In comparison to the only other study presenting age-standardised prevalence conducted in Serbia (8.2 per 100 000),[@R8] the prevalence of CMT in NZ was higher. However, this study highlights that the CMT prevalence of 1 in 6369 identified is far lower than the frequently quoted '1 in 2500 people,[@R13] (ie, 40 per 100 000) identified in one of the first epidemiological studies of CMT. The prevalence was also found to be lower than recent studies conducted in Europe.[@R14] As found in previous studies, CMT1A was the most common form of CMT and proportions of Hereditary Neuropathy with Liability to Pressure Palsy (HNPP) were found to be equivalent between this study and previous literature.[@R16] Of the CMT1A cases, 73.2% had received a genetic test confirming the duplication. However, CMT1X was not the second most common subtype as is usually found. This may be due to the larger proportion of people who were unclassified or categorised as CMT1Other in the current study.

Age-standardised prevalence is important to take country specific population differences (eg, an older or younger population) into account to ensure data are comparable. Our higher prevalence to Serbia is likely to reflect our inclusion of community-based sources of case ascertainment in addition to medical records. However, there may be some unique differences by country that need further investigation. One of the main challenges with previous research is that most studies have only reported crude prevalence which has been found to vary considerably.[@R4] Further work is needed to determine if differences in prevalence are simply due to methodological issues or if there are actual differences in prevalence by country to inform healthcare planning.

Less than half (41.9%) of participants had received a molecular confirmation of diagnosis. While this is comparably lower than the rate of 60.4% reported by the Inherited Neuropathies Consortium Centres,[@R16] this compares favourably with a study of adults in the Ireland which reported a genetic diagnosis rate of 30.5%.[@R9] We were surprised at the low rates of neurophysiology in this population and the findings suggest that increased access and information for patients on genetic and neurophysiological testing is needed. While every attempt was made to check if participants had received a nerve conduction study (including contacting neurologists working in private practice), it is acknowledged that some nerve conduction studies may not have been accessible.

Raw frequencies of numbers of males and females revealed no gender differences, but when age-standardised prevalence was calculated (taking sex differences in the population denominator into account), prevalence was slightly higher in males (16.1 per 100 000) than females (14.5 per 100 000). This finding is comparable to that identified in the Serbian study.[@R8] The higher prevalence of women with axonal CMT may be partly accounted for by CMTX1 cases among boys that can have an earlier onset or more severe disease, whereas there may be preserved nerve conduction values in CMTX1 females.

Given onset of CMT symptoms usually occurs in childhood and adolescence,[@R17] the low prevalence observed in those aged 0--15 years was surprising, particularly given that the mean age of diagnosis was 34 years of age. There was particularly low prevalence in girls (5.5 per 100 000) compared with boys (12.2 per 100 000). The reasons for this gender disparity in infants and children is unclear, but is likely to reflect social biases in identification of early symptoms between girls and boys. In NZ, most cases of childhood CMT are diagnosed based on clinical review and family history. The low number of children identified may reflect the approach of the National Genetic Service, which does not support the genetic testing of asymptomatic children. The findings may also reflect that parents may perceive little benefit in seeking early medical review if the condition is known within the family or delays within the health system in arranging for diagnostic tests. The low number of child cases identified in this study highlights the need for earlier identification and testing of potentially affected children. Indeed, early diagnosis and best practice care have been identified as essential to achieving health improvements for children (and adults) living with rare diseases.[@R18]

The advent of gene panels has facilitated and will continue to facilitate the diagnosis of rare CMT subtypes. In our cohort, one individual was diagnosed with CMT2M (*dynamin 2*) and another with CMT2c (*TRPV4*). It is also worth noting that one patient was diagnosed with CMTX3, a rare subtype, not diagnosable on current gene panels, highlighting the importance of taking an extended family history. One case of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay and one case of Giant Axonal Neuropathy were identified as part of the study but were excluded as they were deemed not to meet the inclusion criteria. However, this opens up debate as to the expanding phenotype of these genetic mutations.

While this study has provided the most comprehensive case ascertainment procedure conducted to date to determine CMT prevalence, it is still likely that some cases of CMT were missed. Consequently, prevalence may still be an underestimate, particularly given the low prevalence in children. Indeed, a recent study based on a neonatal genetic screening programme and found prevalence of the PMP22 deletion associated with HNPP to be as high as 58.9 per 100 000.[@R19] This suggests that not all disease mutation carriers develop the disease at such an extent to be detected based on clinical diagnosis and highlight ascertainment tools employed strongly influence prevalence estimates.

Additionally, as only one region of NZ was included, it is unclear if the findings reflect the whole country. Further confidence in our observed prevalence of subtypes of CMT is reduced as not all participants received a genetic test or neurophysiology. To respect patient privacy and adhere to data sharing policies in NZ, it was difficult to identify family relationships between individually identified patients across different organisations. However, due to low numbers of known affected family members, many of whom were also captured by the study, there was no evidence of any clear founder effects.

Conclusion {#s5}
==========

Age-standardised point prevalence of all CMT cases was 15.7 per 100 000 with higher prevalence in males than females. A small proportion of cases were uniquely identified through community-based sources of case ascertainment.
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